AgingResearch.NewsJoin free

DNA-damaging chemotherapy

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Larry L. Hillblom Foundation and 4 more
  • Cells1

Outcomes

1

Senescence-associated secretory phenotype (SASP)

upin humans1

1 study

  1. DNA-damaging chemotherapy induces senescence-associated secretory phenotype (SASP) in humans.

    “Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy.”

    Humansin prostate cancer patients after DNA-damaging chemotherapy

    Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

    PLoS biology2 Dec 2008

More on Senescence-associated secretory phenotype (SASP)

Latest

Related